Pauling.AI
Pauling.AI accelerates the transition from research idea to validated molecular candidates for drug discovery. The company combines large language models with physics-based molecular simulation methods to generate and evaluate novel small molecules and biologics. It operates as a B2B platform used by research groups and pharmaceutical companies for lead identification and optimization. The platform integrates AI-driven design with simulation-backed validation to prioritize candidates for experimental testing. Pauling.AI collaborates with academic and industry partners to discover molecules across multiple therapeutic areas.
Pauling.AI
Pauling.AI accelerates the transition from research idea to validated molecular candidates for drug discovery. The company combines large language models with physics-based molecular simulation methods to generate and evaluate novel small molecules and biologics. It operates as a B2B platform used by research groups and pharmaceutical companies for lead identification and optimization. The platform integrates AI-driven design with simulation-backed validation to prioritize candidates for experimental testing. Pauling.AI collaborates with academic and industry partners to discover molecules across multiple therapeutic areas.